GSK's Sotrovimab Receives MHRA Approval for COVID-19 Treatment with Demonstrated Activity Against Omicron Variant
Dec 02, 2021 15:14
CST Updated
15:14
GSK
Pharmaceutical R&D Manufacturer
Medicines and Healthcare products Regulatory Agency
The MHRA is an executive agency of the UK Department of Health and Social Care, responsible for ensuring that medicines and medical devices work effectively and are safe and reliable. Established in 2003 through the merger of the Medicines Control Agency and the Medical Devices Agency, the organization employs more than 1,300 staff members.
Gelonghui December 2nd丨GSK stated that preclinical data shows its COVID-19 drug Sotrovimab remains active against Omicron. According to market reports, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved GSK's antibody drug Sotrovimab for COVID-19 treatment.